Dividend investors entering July 2026 have a rare setup: Three of the market’s most reliable income stocks all delivered beat-and-raise first-quarter reports, all hiked their payouts in the past 12 months and all three are riding meaningful momentum into the back half of the year. The thesis is simple. When defensive cash-flow machines start outperforming, income compounding does the heavy lifting while you wait.
Here are three dividend names worth watching closely this month, each chosen for a different reason so they complement rather than duplicate each other in a portfolio.
AbbVie (ABBV)
AbbVie (NYSE:ABBV | ABBV Price Prediction) is the growth-flavored pick of the three. The post-Humira transition is no longer theoretical: Skyrizi posted $4.48 billion in Q1 sales (+31%) and Rinvoq added $2.12 billion (+23%), more than offsetting a 39% Humira decline. Total Q1 2026 revenue hit $15.00 billion, up 12% year-over-year, and management lifted full-year adjusted EPS guidance to $14.08 to $14.28.
The dividend math is what matters here: AbbVie now pays $1.73 per share quarterly, up from $1.64 in 2025 and the streak runs 12 consecutive years as a standalone company since the Abbott spin. Shares are trading around $252 with a forward P/E of 18, which is reasonable given the trailing growth profile. CEO Robert A. Michael said the company is “off to an excellent start in 2026, with first-quarter results exceeding our expectations.”
Bull case: Skyrizi and Rinvoq are now collectively bigger than Humira ever was at peak, neuroscience grew 26%, and the 44% one-year total return shows the market is finally crediting the new growth engines.
Risk: Humira erosion is not finished, a $744 million IPR&D charge dragged Q1 net income lower by 46% year-over-year, and the trailing P/E of 124 reflects how lumpy GAAP earnings can be in biopharma.
Johnson & Johnson (JNJ)
Johnson & Johnson (NYSE:JNJ) is the quality anchor. The company just raised its quarterly dividend to $1.34 from $1.30, extending a streak that now sits at 64 consecutive years of annual increases. That makes JNJ a true Dividend King, and it carries one of only two AAA corporate credit ratings in the United States.
Q1 2026 was a clean beat. Revenue came in at $24.06 billion (+10% YoY), adjusted EPS of $2.70 beat the $2.68 consensus, and management raised full-year guidance to revenue of $100.3 billion to $101.3 billion with adjusted EPS of $11.45 to $11.65. Oncology is the engine: DARZALEX grew 23%, TREMFYA jumped 68% and CARVYKTI climbed 62%. CEO Joaquin Duato called it “a year of accelerated growth and impact.”
Bull case: A beta of 0.256 gives the portfolio ballast, oncology growth is offsetting STELARA biosimilar pressure, and the stock has already delivered a 26% YTD return while still trading below the $257.50 analyst target.
Risk: STELARA created roughly 920 basis points of revenue drag, talc-related litigation produced a $330 million Q1 charge, and the planned Orthopaedics separation introduces execution risk.
Coca-Cola (KO)
Coca-Cola (NYSE:KO) rounds out the trio as the pure defensive staple. The current quarterly payout sits at 53 cents, with the next payment dated July 1. Coca-Cola has now raised its dividend for 64 consecutive years, paid $8.8 billion in dividends during 2025 and remains Berkshire Hathaway’s third-largest holding.
Q1 2026 was the cleanest report of the three. Revenue of $12.47 billion (+12% YoY) beat estimates, EPS of 86 cents beat the 81-cent consensus, organic revenue grew 10% and operating margin expanded to 35% from 33%. Coca-Cola Zero Sugar volume grew 13%. Management raised 2026 comparable EPS growth guidance to 8% to 9% and expects free cash flow near $12.2 billion. New CEO Henrique Braun summarized it: “We’ve had a strong start to the year.”
Retail interest tracks the fundamentals. Reddit sentiment on r/dividendinvesting registered scores of 70 to 72 in early June, with a 62 bullish reading on June 25.
Bull case: A beta of 0.354, raised EPS guidance, and global unit case volume growth led by China, the U.S. and India give KO an unusual combination of stability and modest top-line acceleration. Shares are up 20% YTD at $81.98.
Risk: A $960 million BODYARMOR impairment hit Q4 2025, ongoing IRS tax litigation remains unresolved, and the forward P/E of 25 leaves limited multiple expansion upside if growth slows.
What to Watch in July
The next catalysts arrive quickly. Coca-Cola pays its quarterly dividend July 1, AbbVie’s next ex-dividend date is July 15, and second-quarter earnings season kicks off mid-month. With all three names having raised guidance in Q1, the bar for July reports is whether momentum holds.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks